Payment overview · 2025
General Payments
$342.88
13 reported records · 7 companies
Healthcare provider profile · identity verified
Ryan W Schafer, DO
Allopathic & Osteopathic Physicians|Family Medicine · ARDMORE, OK · NPI 1780650606
Verified facts
What the public records show
CMS Open Payments records show Ryan W Schafer, DO received $342.88 in general payments during 2025 across 13 reported records.
Boston Scientific Corporation accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $136.88 | 39.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.15 | 21.6% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.17 | 12.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.97 | 11.1% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $22.20 | 6.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.27 | 4.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.24 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.88 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $116.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.15 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.15 | 4 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $42.17 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 927 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 120 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 435 | 45 |
| Gabapentin | Gabapentin | 324 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 74 |
| Alprazolam | Alprazolam | 246 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 245 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 217 | 21 |
| Omeprazole | Omeprazole | 215 | 64 |
| Losartan Potassium | Losartan Potassium | 210 | 56 |
| Tramadol Hcl | Tramadol Hcl | 191 | 27 |
| Lisinopril | Lisinopril | 176 | 54 |
| Metformin Hcl | Metformin Hcl | 163 | 43 |
| Meloxicam | Meloxicam | 153 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 146 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 34 |
| Diazepam | Diazepam | 139 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 43 |
| Eliquis | Apixaban | 130 | 30 |
| Ibuprofen | Ibuprofen | 122 | 38 |
| Trazodone Hcl | Trazodone Hcl | 121 | 34 |
| Estradiol | Estradiol | 117 | 37 |
| Ozempic | Semaglutide | 112 | 23 |
| Potassium Chloride | Potassium Chloride | 111 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 36 |
| Furosemide | Furosemide | 105 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 14 |
| Carisoprodol | Carisoprodol | 95 | 17 |
| Allopurinol | Allopurinol | 92 | 26 |
| Clonazepam | Clonazepam | 91 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 28 |
| Trulicity | Dulaglutide | 88 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 85 | suppressed |
| Methadone Hcl | Methadone Hcl | 84 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 19 |
| Fentanyl | Fentanyl | 80 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 80 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 80 | 18 |
| Simvastatin | Simvastatin | 75 | 22 |
| Pregabalin | Pregabalin | 72 | 16 |
| Sertraline Hcl | Sertraline Hcl | 72 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 19 |
| Lorazepam | Lorazepam | 67 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 17 |
| Glipizide | Glipizide | 64 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 18 |
| Donepezil Hcl | Donepezil Hcl | 58 | 13 |
| Morphine Sulfate | Morphine Sulfate | 57 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 41 |
| Temazepam | Temazepam | 50 | suppressed |
| Topiramate | Topiramate | 50 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 43 |
| Carvedilol | Carvedilol | 48 | 16 |
| Celecoxib | Celecoxib | 48 | 14 |
| Azithromycin | Azithromycin | 47 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Sucralfate | Sucralfate | 43 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Irbesartan | Irbesartan | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Atenolol | Atenolol | 32 | 12 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Torsemide | Torsemide | 31 | 15 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Minoxidil | Minoxidil | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.88 · 13 records | Boston Scientific Corporation | GIVLAARI, Intracept, KEVEYIS, Kerendia, Ozempic, Quviviq, Rybelsus, VOQUEZNA, WATCHMAN Access System | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error